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Josef Stehlik, MD, Jennifer A. Cowger, MD, MS, Robert H. Habib, PhD, James K. Kirklin, MD,
Francis D. Pagani, MD, PhD, and Pavan Atluri, MD
Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, Minnesota; John and James
Kirklin Institute for Research in Surgical Outcomes, School of Medicine, University of Alabama at Birmingham,
Birmingham, Alabama; Department of Medicine, Division of Cardiology, Feinberg School of Medicine Northwestern,
Chicago, Illinois; Department of Surgery, Division of Cardiothoracic Surgery, Medical University of South Carolina,
Charleston, South Carolina; Department of Medicine, Division of Cardiovascular Medicine, University of Utah, Salt
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of Alabama at Birmingham, Birmingham, Alabama; Department of Cardiac Surgery, University of Michigan, Ann Arbor,
Michigan; and Department of Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia,
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ABSTRACT
BACKGROUND On June 3, 2021 Medtronic, Inc announced discontinuation of the HVAD left ventricular assist device.
The purpose of this analysis was to provide summary data on surgical risks of HVAD to HeartMate 3 exchange and
compare survival after HVAD to HeartMate 3 exchange to survival after primary HVAD implantation.
METHODS Three cohorts within The Society of Thoracic Surgeons Intermacs database were identiﬁed: primary HVAD
implant cohort (January 2017 to March 2021, n [ 3797), HVAD to HeartMate 3 exchange cohort (December 2017 to
March 2021, n [ 45), and HVAD to HVAD exchange cohort (January 2017 to March 2021, n [ 234). Mortality after HVAD
to HeartMate 3 exchange was modeled and compared with the constant hazard phase for risk of mortality while on
continued HVAD support. As a secondary analysis outcomes and survival were compared between patients who underwent HVAD to HeartMate 3 and HVAD to HVAD exchange.
RESULTS HVAD to HeartMate 3 exchange was associated with signiﬁcantly reduced survival compared with survival while
remaining on HVAD support (6 months after exchange, 73.8% [70% conﬁdence interval, 68.6-77.8] vs 79.0% [70% conﬁdence
interval, 78.3-79] for continued HVAD support). Compared with HVAD to HVAD exchange, survival was higher after replacement
with HeartMate 3 (1 year: 85.9% [70% conﬁdence interval, 79.5-90.5] vs 66.6% [70% conﬁdence interval, 63.0-70.0], P [ .009).
CONCLUSIONS Compared with continued support on HVAD, an exchange to HeartMate 3 was found to be associated with a
signiﬁcant increase in mortality. For patients who required pump exchange on HVAD support, exchange to HeartMate 3 demonstrated superior survival. Currently there is insufﬁcient evidence to support elective exchange from an HVAD to HeartMate 3.
(Ann Thorac Surg 2021;-:---)
ª 2021 by The Society of Thoracic Surgeons
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n June 3, 2021 Medtronic, Inc (Minneapolis,
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Medtronic relating to this speciﬁc device malfunction

cohort (n ¼ 45 [ﬁrst occurrence of an HVAD to HeartMate

occurred in December 2020. At that time an internal

3 exchange reported in STS Intermacs was in December

pump component, the impellor, was believed to be

2017], implant dates December 2017 to March 2021), and

responsible for this speciﬁc failure mode, and the

a contemporary cohort consisting of patients undergoing

responsible device components were traced to 3 isolated

an HVAD to HVAD exchange (n ¼ 234, implant dates

lots of HVAD devices. Subsequently reports of device

January 2017 to March 2021) (Figure 1).

failures continued beyond the 3 lots initially identiﬁed,

Patients were excluded if age at the time of surgery

and a common root cause of this problem could not be

was <19 years. For the ﬁrst cohort (primary HVAD

determined in all cases. The rate of device malfunction

implant), patients receiving concomitant right ventric-

for this mode of failure, outside of the 3 speciﬁed lots,

ular assist device (RVAD) support concomitant with the

was reported as 0.4%. With the inability to address these

initial LVAD implant were excluded from the study

HVAD critical device malfunctions, coupled with data

cohort. Patients receiving a subsequent RVAD after

demonstrating the clinical superiority of the Heart-

leaving the operating room from the initial LVAD

Mate 3,1,2 Medtronic stopped the distribution and sale

implant were included. Patients receiving a concomitant

of the HVAD system.

RVAD at the time of LVAD exchange were included for

With Medtronic’s decision the HeartMate 3 is now the

the second (HVAD to HeartMate 3 exchange; 2/42 [4.7%]

only US Food and Drug Administration–approved dura-

received a concomitant RVAD at the ﬁrst exchange) and

ble LVAD in the United States for both new implants and

third (HVAD to HVAD exchange; 9/234 [3.8%] received a

pump exchanges. This also holds true for a large part of

concomitant RVAD at the ﬁrst exchange) study cohorts.

the global community. A number of important issues

Patients receiving any other type of durable mechanical

have arisen as to how to manage patients currently

circulatory support device were excluded from the

supported with the HVAD pump with little data for

analysis. The study period was limited to January 2017 to

guidance. Should patients on HVAD support be offered

April 30, 2021 to match the time period when HVAD to

exchange for a device-related complication only (ie,

HeartMate 3 exchanges were reported to the STS

pump thrombosis), or should HVAD pumps be electively

Intermacs.

changed to the HeartMate 3 to reduce the risk of patient

For each cohort baseline characteristics at the time of

harm from a potential device malfunction related to a

exchange (exchange cohorts) or the time of ﬁrst im-

failure to restart event? In addition little data have been

plantation (primary HVAD cohort) are presented in

published with respect to the surgical risks and mortality

Table 1. Continuous variables were evaluated for

expected after an HVAD to HeartMate 3 exchange,

normality and are presented as mean  SD or median

particularly when considering the additional surgical

(interquartile range), as appropriate. Categorical vari-

complexity

ables are displayed as counts and percents.

of

device

exchange

and

associated

morbidity.

For the primary HVAD implant cohort, follow-up

The objective of the present study was to provide

began at initial device implant, and patients were

summary data of the surgical risks of an HVAD to

censored at transplant, device exchange, cessation of

HeartMate 3 exchange and to compare survival after an

device support, or device explant without exchange. For

HVAD to HeartMate 3 exchange to survival after a

the exchange subgroups, follow-up began at the device

contemporary,

also

exchange and continued while the exchange device was

compared surgical outcomes and survival between

in place. Additional LVAD exchange procedures in the

HVAD to HeartMate 3 and HVAD to HVAD exchange

exchange subgroups were not considered as censoring

populations. We hypothesized that survival after an

events in the analysis unless the device was switched to

HVAD to HeartMate 3 exchange would not be superior to

a different brand of device. Of the 234 patients under-

survival on continued HVAD support.

going an HVAD to HVAD exchange 5 patients went on to

PATIENTS AND METHODS

receive a subsequent exchange to a HeartMate 3 (third

This retrospective analysis of The Society of Thoracic

second exchange. The last date of follow-up was June 15,

Surgeons (STS) Intermacs registry was performed by the

2021. STS Intermacs subject status (alive on support,

primary

HVAD

implant.

We

device). These patients were censored at the time of the

Data Coordinating Center at the University of Alabama at

exchanged, transplanted) and dates were veriﬁed with

Birmingham. The primary analysis compared survival

clinical sites as of June 15, 2021 for the 45 patients un-

after an HVAD to HeartMate 3 exchange to survival after

dergoing HVAD to HeartMate 3 exchange.

a contemporary, primary HVAD implant. A secondary

To compare survival after an HVAD to HeartMate 3

analysis compared survival after an HVAD to HeartMate

exchange with that of survival after a primary HVAD

3 exchange to survival after an HVAD to HVAD ex-

implant, a multiphase parametric survival curve was ﬁt

change. To complete these comparisons 3 study cohorts

to the data of the primary HVAD implant cohort and

were identiﬁed: a contemporary cohort undergoing pri-

HVAD to HeartMate 3 exchange cohort (Supplemental

mary HVAD implant (n ¼ 3797, implant dates January

Figures 1 and 2). This technique displays the changing

2017 to March 2021), an HVAD to HeartMate 3 exchange

hazard for an event over time4 and identiﬁes when
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FIGURE 1 Study cohort and subgroups. (RVAD, right ventricular assist device.)

survival reaches a constant hazard phase for risk of

Institute Inc, Cary, NC), and a P < .05 was considered

mortality for the primary HVAD cohort (starting at

statistically signiﬁcant.

approximately 6 months after primary HVAD implant).

This study was reviewed and approved by the STS

Parametric survival after an HVAD to HeartMate 3 ex-

Research Center. The ﬁndings and conclusions herein

change was then overlaid onto the parametric survival of

represent those of the authors and not those of the STS

the HVAD curve at 6 months. Seventy percent conﬁ-

(Chicago, IL), Abbott Labs, Medtronic, Inc, or the US

dence intervals were included to indicate statistical

Food and Drug Administration.

signiﬁcance of approximately P ¼ .05 (Figure 2 and
Supplemental Figure 3).5,6

RESULTS

HVAD to HeartMate 3 and HVAD to HVAD exchange
patient characteristics at the time of exchange were

STUDY COHORTS. For the primary HVAD implant sub-

compared. Normally distributed continuous variables

group (n ¼ 3797) mean age was 56  13.2 years and 73%

were compared with Student t tests and nonnormally

were men (2768/3797), with 22.9% (869/3797) STS Inter-

distributed

Mann-Whitney

macs Proﬁle 1 (Table 1). The mean age of the HVAD to

tests. Categorical variables were compared using

HeartMate 3 exchange subgroup (n ¼ 45) was 53  13

Pearson’s c2 test or Fisher’s exact test as appropriate.

years, 69% were men (31/45), and 16% (7/45) were STS

Survival probabilities after exchange were calculated

Intermacs Proﬁle 1. Overall there was a relatively high

using the Kaplan-Meier method, and survival was

proportion of patients on an intraaortic balloon pump (9%

compared using the log rank test. Additionally out-

[4/45]) and/or ventilator support (9% [4/45]) at the time of

comes were examined using the Fine-Gray competing

the LVAD exchange (Table 1). The HVAD to HVAD ex-

variables

with

the

outcomes analysis in which multiple mutually exclu-

change subgroup (n ¼ 234) was similar in age and acuity to

sive outcomes (alive on LVAD support, death, cessa-

both the HVAD to HeartMate 3 exchange and the primary

tion of support, and transplant) are tracked over time.

HVAD implant subgroups (Table 1). The median follow-up

At any point in time the sum of the proportion (%) of

for the 3 cohorts was 14.5 months (interquartile range, 7.6-

patients in each outcome category equals 100%.

23.9) for the HVAD to HeartMate 3 subgroup, 13.0 months

Finally survival after an HVAD to HVAD exchange was

(interquartile range, 5.0-27.2) for the primary HVAD

stratiﬁed by year of exchange (2017, 2018-2019, 2020-

implant subgroup, and 8.3 months (interquartile range,

2021). All analyses were completed with SAS 9.4 (SAS

2.7-17.1) for the HVAD to HVAD subgroup.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 16, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

3

4

COGSWELL ET AL

Ann Thorac Surg
2021;-:---

HVAD TO HEARTMATE 3 EXCHANGE

TABLE 1

Patient Characteristics of the Study Cohorts
HVAD to HeartMate Exchange
Cohort Exchange (n ¼ 45)

Contemporary Primary HVAD
Implant Cohorta (n ¼ 3797

HVAD to HVAD Exchange Cohort
(n ¼ 234)

53.2 ± 13.2b

56.0 ± 13.2

54.1 ± 13.6b

Male

31 (68.9)

2768 (72.9)

175 (74.8)

White

26 (57.8)

2336 (61.5)

160 (68.4)

10 (22.2%)b

740 (19.5)

62 (26.6)b

Body surface area

2.2 ± 0.3b

2.0 ± 0.3

2.1 ± 0.3b

Body mass index, kg/m2

30.8 ± 6.8b

28 ± 7.6

30.3 ± 7.9b

Ischemic cardiomyopathy

24 (53.3)b

1569 (41.3)

103 (44.0)b

Age, y

Bridge to transplant, listed

Society of Thoracic Surgeons
Intermacs Proﬁle
1

7 (15.6)b

869 (22.9)

53 (22.8)b

2

6 (13.3)b

1315 (34.6)

64 (27.5)b

2 (4.4)

1240 (32.7)

28 (12.0)b

30 (66.7)b

373 (9.8)

88 (37.8)b

Prior coronary artery bypass graft

7 (15.6)

641 (16.9)

39 (16.7)

Intraaortic balloon pump

4 (8.9)b

1299 (34.2)

18 (7.7)b

Extracorporeal membrane
oxygenation

1 (2.2)b

324 (8.5)

18 (7.7)b

Dialysis

2 (4.4)b

174 (4.6)

13 (5.6)b

3
4-7

Ventilator
Creatinine, mg/dL

b

b

4 (8.9)

558 (14.7)

23 (9.9)b

1.4 ± 0.7b

1.4 ± 0.6

1.8 ± 1.0b

21.4 ± 11.5b

29.5 ± 17.4

27.9 ± 17.4b

Albumin, g/dL

3.5 ± 0.6b

3.4 ± 0.6

3.5 ± 0.6b

Bilirubin, mg/dL

1.6 ± 1.3b

1.3 ± 1.6

2.0 ± 1.8b

Blood urea nitrogen, mg/dL

a

All data for the cohort were reported at the time of primary HVAD implant; bReported at the time of exchange. Values are mean ± SD or n (%).

SURVIVAL COMPARISON BETWEEN HVAD TO HEARTMATE 3

statistically signiﬁcant (ie, separation of the 70% conﬁ-

EXCHANGE VS CONTEMPORARY HVAD SUPPORT. For a

dence intervals between curves supporting a P < .05)5,6

primary HVAD implantation there was a high early

increase in mortality was noted, represented in Figure 2

hazard for death followed by a rapidly declining post-

as an increase in the early mortality hazard after ex-

operative hazard phase that transitioned to a constant

change when compared with the constant hazard phase

mortality hazard at approximately 6 months (Figure 2

for risk of mortality of 0.1 for those maintained on HVAD

and Supplemental Figures 1 and 3). An HVAD to Heart-

support after primary implant.

Mate 3 exchange was also characterized by an early
hazard for risk of death with rapidly declining risk that

SURGICAL COMPARISON BETWEEN PUMP EXCHANGE

quickly transitioned to a constant hazard of risk for

OUTCOMES:

death (Figure 2 and Supplemental Figures 2 and 3).

HVAD. The indication for pump exchange, length of

Although the constant hazard of risk for mortality after

stay, and postsurgical complications for both the

an HVAD to HeartMate 3 exchange was less than the

HVAD to HeartMate 3 and HVAD to HVAD pump ex-

constant hazard of risk for mortality after a primary

change cohorts are summarized in Supplemental Ta-

HVAD implant, there was a substantial early post-

ble 1. Of note given the ability to indicate multiple

operative risk of death associated with the HVAD to

causes for exchange on STS Intermacs Adverse Event

HeartMate 3 exchange operation.

forms, the aggregate is >100%. For the HVAD to

HVAD

TO

HEARTMATE

3

VS

HVAD

TO

Comparison of these risks is depicted in Figure 2 for a

HeartMate 3 exchange subgroup the indications for

hypothetical HVAD to HeartMate 3 device exchange

exchange were pump thrombosis in 67%, device mal-

occurring at 6 months vs continued support after a pri-

function in 11%, device infection in 20%, and other in

mary HVAD implant beyond 6 months. Mortality was

1%. For the HVAD to HVAD exchange cohort in-

highest early after primary HVAD implant, reaching a

dications were pump thrombosis in 61%, device mal-

constant hazard phase of risk for mortality at approxi-

function in 36%, device infection in 6%, and other in

mately 6 months after LVAD implantation (Figure 2 and

6%. Compared with the HVAD to HVAD exchange,

Supplemental Figures 1 and 3). In the subgroup of pa-

bypass time for the HVAD to HeartMate 3 was

tients undergoing HVAD to HeartMate 3 exchange a

considerably longer (median 139 minutes vs 75
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FIGURE 2 Parametric model estimate of survival after HVAD to HeartMate 3 (HM3) exchange and contemporary, primary
HVAD implantation after survival for the primary HVAD implantation reaches the constant hazard phase of risk for death.
Curves of parametric model survival estimates comparing the mortality of patients remaining on support with the HVAD left
ventricular assist device (black) vs those who have undergone an exchange to the HM3 (red). Note that time begins at 6
months (6m) after primary implantation of the HVAD. The dash lines represent the 70% conﬁdence intervals and do not
overlap in the 6 months after HVAD to HM3 exchange supporting a statistical signiﬁcance of P [ .05.5,6 Survival at 1-month
after HVAD to HM3 exchange was 79.4% (70% conﬁdence interval, 75.0-82.2) compared with survival of 83.8% (70%
conﬁdence interval, 83.2-84.4) if remaining on continued HVAD support (7 months from initial HVAD implant). Survival at 6months after HVAD to HM3 exchange was 73.6% (70% conﬁdence interval, 68.6-77.8) compared with survival of 79.0% (70%
conﬁdence interval, 78.3-79.6) if remaining on continued HVAD support (12 months from initial HVAD implant).

minutes, P < .0001), as was the need for concomitant

exchange only 51.9% remained alive on support at 12

surgery (71% vs 43%, P < .001). Postoperative RVAD

months, with 14.9% receiving a transplant and 30.7%

use, prolonged inotrope use, infection, stroke, and

dying (Supplemental Figure 6B).

need for dialysis were similar, with the HVAD to
HeartMate 3 group requiring an RVAD in 6.7% (3/45)
and prolonged inotropes in 33% (13/39) of cases. The

COMMENT

occurrence of postoperative infection was 31% (14/45),

The ADVANCE, ENDURANCE, and ENDURANCE Sup-

need for dialysis was 12.9% (5/39), and stroke was 9%

plemental clinical trials7-9 established the long-term

(4/45). Of the HVAD to HeartMate 3 exchanges 11%

safety and efﬁcacy of the HVAD system (Medtronic Inc)

died (5/45) during the exchange hospitalization.

as durable LVAD support for patients with advanced

Late survival after exchange was higher in those

heart failure. Initially manufactured by HeartWare, Inc

exchanged to a HeartMate 3 (1 year: 86% vs 67%, P ¼

the HVAD technology was subsequently acquired by

.009) (Supplemental Figure 4).

Medtronic in 2016 with a focus to further advance HVAD

Survival after an HVAD to HVAD exchange stratiﬁed

development, including design of a totally implantable

by year of device exchange (2017, 2018-2019, 2020-21) is

platform.10 The HVAD served a key role in supporting

shown in Supplemental Figure 5. There was no signiﬁ-

thousands of patients, both for destination therapy and

cant difference in survival across years.

bridge to transplant applications. Several key design
attributes advanced the application of this technology

COMPETING OUTCOMES. For patients undergoing an

for both adult and pediatric patients, including an

HVAD to HeartMate 3 exchange the proportion remain-

intrapericardial design that minimized surgical dissec-

ing alive on support at 12 months was 80.8%, with 5.2%

tion and improved ease of surgical implant, reduced size

receiving a transplant and 14% dying (Supplemental

permitting implantation in smaller patients, ease of

Figure 6A). For patients undergoing an HVAD to HVAD

application to novel support conﬁgurations including

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
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use as a durable RVAD for biventricular assist, and po-

LIMITATIONS. The results of the present analysis, how-

tential to implant using a minimally invasive approach

ever, must be interpreted acknowledging that the sub-

with an anterior lateral thoracotomy incision and

group undergoing an HVAD to HeartMate 3 exchange

without cardiopulmonary bypass.

underwent a device exchange for cause (ie, pump

Since the commercial availability of the HVAD device

thrombosis or device infection) and were by deﬁnition

in 2012 a next-generation device, the HeartMate 3 (Abbott

sicker than patients who would be undergoing an elec-

Labs), has undergone evaluation in a large, multicenter,

tive device exchange. In addition because of the small

randomized, prospective clinical trial and received U.S.

sample size, we were not able to analyze outcomes by

Food and Drug Administration approval for short-term

exchange indication or risk adjustment for severity of

circulatory support indication in 2017 and long-term

illness at the time of exchange. It is likely that surgical

support

indication

in

2019.11,12

With

commercial

experience with device exchanges over time will lead to

approval of the HeartMate 3 and in the absence of clinical

improved outcomes with an HVAD to HeartMate 3 ex-

trial data directly comparing the HVAD with HeartMate 3,

change, as has been observed with other LVAD surgeries

a number of comparative effectiveness studies to the

over time.15 However when comparing survival after an

HVAD device have been performed from clinical registries

HVAD to HVAD exchange, stratiﬁed by year of device

and administrative databases and have demonstrated a

exchange, signiﬁcant improvements in survival were not

signiﬁcantly increased risk of stroke and mortality for the

observed with our data. Thus caution must be used in

HVAD compared with the HeartMate 3.1,2,13,14 Coupled

assessing the impact of surgical experience in improving

with recent concerns over the potential of internal pump

outcomes after device exchanges. The exchange cohort

failures resulting in a delayed or failed restart in roughly

analyzed in this study represents the ﬁrst 45 patients

100 cases, Medtronic decided to remove the HVAD device

who underwent this procedure and reported to STS

from commercial distribution and sale.

Intermacs. For these reasons this analysis will likely

The decision to remove the HVAD from commercial
availability has raised concern regarding the optimal

need to be repeated as experience grows to understand
the risk vs beneﬁt of future exchanges.

management of patients on existing HVAD support and

The STS Intermacs registry relies on clinical sites for

the risk-to-beneﬁt ratio of device exchange in those on

completeness and accuracy of data reporting and may not

uncomplicated device support to prevent future compli-

have included all events for the HVAD to HeartMate 3

cations, including the potential for device restart failure.

exchange procedures and their related events and out-

Data from this study demonstrate that compared with

comes. However the STS Intermacs registry, a component

contemporary survival after primary implant of the HVAD

of the STS National Databases, undergoes routine data

System, exchange to a HeartMate 3 was associated with

audits for completeness and accuracy performed by in-

increased early-phase mortality, particularly in the initial

dependent auditors. Importantly this analysis was

6 months after the exchange operation. When comparing

signiﬁcantly limited by sample size, and there were

outcomes after a nonelective HVAD to HeartMate 3 ex-

insufﬁcient numbers of patients to perform detailed sta-

change with a nonelective HVAD to HVAD exchange

tistical analyses to understand characteristics associated

postsurgical complications were similar, yet late survival

with poor outcomes or characteristics that may improve

was superior when an HVAD was changed to the Heart-

patient selection. Further because of sample size, risk

Mate 3 vs exchanged with another HVAD.

adjustment of patient characteristics were not performed.

Despite the increases in technical difﬁculty of
exchanging an HVAD to HeartMate 3 compared with an

CONCLUSION. Compared with contemporary survival

HVAD to HVAD exchange and longer duration of cardio-

after primary HVAD implantation, an HVAD to Heart-

pulmonary bypass times, these data suggest that patients

Mate 3 exchange is associated with a signiﬁcant increase

on HVAD support requiring a device exchange are not

in early mortality. Thus for patients currently supported

disadvantaged by replacement with the HeartMate 3

on a normally functioning HVAD device, there is insuf-

technology. In fact late survival appears to be superior

ﬁcient evidence to support a strategy of elective ex-

and is consistent with previous observations of compar-

change to the HeartMate 3. For patients who required a

isons of overall survival when primary HVAD implants

device exchange while on HVAD support, exchange to

were compared with primary HeartMate 3 implants.13,14

the HeartMate 3 compared with exchange to an HVAD

Thus the increase in surgical complexity in an HVAD to

demonstrated superior late survival. Follow-up analyses

HeartMate 3 exchange compared with an HVAD to HVAD

are warranted to determine if changes to these current

exchange does not increase operative risk. Collectively

recommendations are necessary.

these data suggest there is insufﬁcient evidence, to date,
to support elective exchange from HVAD to HeartMate 3;
however when an exchange is necessary, exchange to a
HeartMate 3 is associated with late survival beneﬁt.

The data for this research were provided by The Society of Thoracic
Surgeons’ National Database Access and Publications Research Program.
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